Mindflair PLC
16 July 2026
16 July 2026
Mindflair plc
("Mindflair" or the "Company")
New investment in a clinical AI dental diagnostics business
Mindflair plc, the AIM-quoted company focused on investing in Artificial Intelligence ("AI") related technology, is pleased to note that Sure Valley Ventures' second fund ("SVV2"), in which Mindflair holds an interest, has led a £1.7 million pre-seed investment round into a clinical AI dental diagnostics business, BeCertain.
The round is also supported by Innovate UK's Investor Partnership Growth Catalyst programme and will fund further product development and commercialisation.
BeCertain is developing an AI software assistant to support dentists in interpreting 2D intraoral X-rays. The platform is intended to improve diagnostic reliability and operational efficiency while retaining clinician oversight and protecting patient data.
Around 20 million dental X-rays are taken in the UK each year, but interpretation can vary between clinicians. BeCertain's proprietary uncertainty-aware AI is designed to identify common conditions, including tooth decay, bone loss, infections and restoration defects, and provide calibrated confidence levels to help clinicians assess its output, particularly in complex or unclear cases.
The technology was developed through research led by Dr Yunpeng Li, Reader in AI & Digital Oral Health at King's College London, and Professor Owen Addison, Professor of Oral Rehabilitation and an Honorary NHS Consultant in Restorative Dentistry. Its initial development was supported by a £1.75 million NIHR i4i Product Development Award.
Nicholas Lee, Director of Mindflair plc, commented:
"BeCertain is applying specialist AI to a clear clinical need, combining machine learning and dental expertise to support more consistent diagnosis while retaining clinician oversight. The funding will support the next stage of product development and commercialisation."
The Directors of the Company are responsible for the release of this announcement. The person who arranged for the release of this information is Nicholas Lee, a director of the Company.
Enquiries:
|
Mindflair plc Nicholas Lee, Director |
Tel: +44 (0) 20 3368 8961 |
|
Nominated Adviser Cairn Financial Advisers LLP Liam Murray / Ludovico Lazzaretti Joint Broker Shard Capital Partners LLP Damon Heath |
Tel: +44 (0) 20 7213 0880 Tel: +44 (0) 20 7186 9950 |
|
Joint Broker AlbR Capital Limited Duncan Vasey/Lucy Williams |
Tel: +44 (0) 20 7469 0935 Tel: +44 (0) 20 7469 0936 |
Notes to Editors
Mindflair plc (AIM: MFAI) is an investment company providing investors with access to a portfolio of next generation technology businesses focused on AI with significant growth potential. The Company is building an investment portfolio of high-tech businesses focused on Artificial Intelligence, across such areas as Cyber Security, Machine Learning, Immersive Technologies and Big Data, which the Board believes demonstrate evidence of traction and the potential for exponential growth, due to increasing global demand for development in these sectors. For further information, visit: http://www.mindflair.tech/.
BeCertain is a UK clinical AI company spun out of King's College London and the University of Surrey. It is developing an uncertainty-aware AI assistant for dental X-ray interpretation that provides calibrated confidence levels to support clinical decision-making while protecting patient data. Further information is available at www.becertain.ai.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.